Don't Forget - the Deadline for Adopting an Expanded Access Policy Under the 21st Century Cures Act is Looming

January 27, 2017 Alerts and Newsletters

As many of you are aware, the 21st Century Cures Act (Pub. L. 114-255) ("Cures Act") was signed into law by President Barack Obama on December 13, 2016.

Under Section 3032 of the Cures Act ("Section 3032"), pharmaceutical companies are generally required to have publicly available policies explaining how the company evaluates and responds to patient requests for certain experimental drugs outside of clinical trials. The deadline for adopting these policies with respect to a particular investigational drug is the later of February 12, 2017 or the first initiation of a phase 2 or 3 study of the investigational drug. For those of you who have investigational drugs that are already in phase 2 or 3, the February 12, 2017 deadline is approaching fast.

Section 3032 requires manufacturers or distributors of investigational drugs for diagnosing, monitoring, or treating serious diseases or conditions to develop and make publicly available (e.g., on the company's website) the manufacturer's policy for responding to requests for so-called "expanded access" use of the drugs. The policy must include the following information:

  • contact information for the manufacturer or distributor for expanded access requests, in order to facilitate communication regarding such requests;
  • procedures for making expanded access requests;
  • the manufacturer's or distributor's general criteria for reviewing and responding to expanded access requests for individual patients;
  • the anticipated length of time for the manufacturer or distributor to acknowledge receipt of expanded access requests; and
  • a link or reference to the clinical trial record included in the clinical trial registry data bank maintained by the National Institutes of Health pursuant to section 402(j) of the Public Health Service Act, which includes a field specifying whether or not there is expanded access to an investigational drug and, if so, how to obtain information about such access.

While manufactures and distributors of investigational drugs must make their expanded access policy publically available, nothing in Section 3032 (or in the Cures Act more broadly) requires these manufacturers and distributors to grant an individual patient's request for expanded access to an investigational drug. Accordingly, an individual patient's expanded access request can be denied for any reason, provided such denial is consistent with the published policy. Additionally, under Section 3032, manufacturers and distributors of investigational drugs are entitled to revise their expanded access policies at any time.

For more information regarding Section 3032, or for assistance drafting your expanded access policy, please contact Andrew Rusczek.

This communication is intended for general information purposes and as a service to clients and friends of Verrill Dana, LLP. This publication, which may be considered advertising under the ethical rules of certain jurisdictions, should not be construed as legal advice or a legal opinion on any specific facts or circumstances, nor does it create attorney-client privilege.

Firm Highlights


Conflicts of Interest

Reviewed medical center's systems, policies and procedures for identifying, assessing, and managing investigator and institutional conflicts of interest.


The Regulatory Sprint is Over - What’s at the Finish Line Under the New Stark and AKS Final Rules?

The U.S. Department of Health and Human Services (HHS) completed its “Regulatory Sprint” by finalizing changes to regulations pertaining to two federal fraud and abuse laws. On December 2, 2020, the Centers for Medicare...


HHS Confirms Providers’ Right to 340B Discount Pricing for Contract Pharmacies

As a holiday gift to providers, the U.S. Department of Health and Human Services (HHS) General Counsel recently issued a strongly worded Advisory Opinion indicating that federal law requires drug manufacturers to deliver covered...


“If I've told you once, I've told you eight times…” HHS OIG Issues Another Audit Report on Hospitals’ Failure to Report Credits for Explanted Cardiac Devices and Lays the Groundwork Collection of Overpayments


Multi-Site Global Research

Developed and negotiated site and coordinating center agreements in connection with a multi-site, international, National Institutes of Health (NIH)-funded study, and advised on regulatory issues related to the conduct of the study and subsequent...


European Union GDPR—Institution

Counseled a preeminent health system and academic medical center on its compliance with the European Union General Data Protection Regulation (GDPR) in relation to its clinical and research activities, including its international research studies...


Nearly 80 Verrill Attorneys Recognized by Best Lawyers® 2021, Including a Dozen Named Lawyers of the Year

(August 24, 2020) – Nearly 80 Verrill attorneys were recognized as "Best Lawyers" by Best Lawyers® 2021 , including 12 attorneys named “Lawyer of the Year,” a distinguished recognition for only a single lawyer...


Common Rule

Guided multiple clients through the implementation of the revised HHS regulations (the "Common Rule"), including reviewing and revising policies and procedures, and assisting with institutional approaches to implementation.


Michael K. Fee to Lead Verrill’s Nationally-Recognized Health Care and Life Sciences Practice Amidst Recent Changes

(August 31, 2020) – Verrill is pleased to announce Michael K. Fee as the new leader of Verrill’s nationally-recognized Health Care & Life Sciences Group. The Group has a long history of representing a...


340B Providers Get Partial Relief from New Dispute Resolution Regulation

1. 340B ADR Process Established At long last, more than ten years after Congress directed it to do so, HHS has finalized an alternative dispute resolution (“ADR”) process for both providers and pharmaceutical manufacturers...

Contact Verrill at (855) 307 0700